Other analysts have also recently issued research reports about the stock. Oppenheimer assumed coverage on shares of Kadmon in a research note on Wednesday, June 26th. They set an “outperform” rating and a $6.00 target price for the company. Zacks Investment Research cut shares of Kadmon from a “buy” rating to a “hold” rating in a research note on Saturday, July 27th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $7.93.
KDMN traded down $0.02 on Thursday, reaching $2.43. The stock had a trading volume of 351,348 shares, compared to its average volume of 781,525. Kadmon has a 12-month low of $1.63 and a 12-month high of $4.39. The company has a current ratio of 3.89, a quick ratio of 3.85 and a debt-to-equity ratio of 0.60. The company has a 50-day moving average price of $2.20. The company has a market cap of $339.24 million, a P/E ratio of -2.36 and a beta of 2.08.
Several hedge funds have recently added to or reduced their stakes in the company. Vivo Capital LLC increased its stake in shares of Kadmon by 20.6% during the first quarter. Vivo Capital LLC now owns 12,606,605 shares of the company’s stock worth $33,281,000 after purchasing an additional 2,152,060 shares in the last quarter. BlackRock Inc. increased its stake in shares of Kadmon by 1.6% during the fourth quarter. BlackRock Inc. now owns 6,874,443 shares of the company’s stock worth $14,299,000 after purchasing an additional 105,874 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of Kadmon during the first quarter worth about $4,397,000. Geode Capital Management LLC increased its stake in shares of Kadmon by 9.5% during the fourth quarter. Geode Capital Management LLC now owns 1,100,657 shares of the company’s stock worth $2,289,000 after purchasing an additional 95,907 shares in the last quarter. Finally, AE Wealth Management LLC grew its stake in Kadmon by 52.9% during the 2nd quarter. AE Wealth Management LLC now owns 532,855 shares of the company’s stock valued at $1,098,000 after acquiring an additional 184,364 shares in the last quarter. 75.56% of the stock is owned by institutional investors and hedge funds.
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Read More: Conference Calls and Individual Investors
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.